JP2013528563A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013528563A5 JP2013528563A5 JP2012544363A JP2012544363A JP2013528563A5 JP 2013528563 A5 JP2013528563 A5 JP 2013528563A5 JP 2012544363 A JP2012544363 A JP 2012544363A JP 2012544363 A JP2012544363 A JP 2012544363A JP 2013528563 A5 JP2013528563 A5 JP 2013528563A5
- Authority
- JP
- Japan
- Prior art keywords
- ophthalmic composition
- composition according
- retinal
- retinopathy
- degrees
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 16
- 230000000007 visual effect Effects 0.000 claims 7
- 208000017442 Retinal disease Diseases 0.000 claims 5
- 238000005259 measurement Methods 0.000 claims 5
- 210000001525 retina Anatomy 0.000 claims 3
- 230000002207 retinal effect Effects 0.000 claims 3
- 230000035945 sensitivity Effects 0.000 claims 3
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims 2
- 206010038923 Retinopathy Diseases 0.000 claims 2
- 230000006870 function Effects 0.000 claims 2
- XXUPXHKCPIKWLR-JHUOEJJVSA-N isopropyl unoprostone Chemical compound CCCCCCCC(=O)CC[C@H]1[C@H](O)C[C@H](O)[C@@H]1C\C=C/CCCC(=O)OC(C)C XXUPXHKCPIKWLR-JHUOEJJVSA-N 0.000 claims 2
- 230000000699 topical effect Effects 0.000 claims 2
- 229950008081 unoprostone isopropyl Drugs 0.000 claims 2
- 206010003694 Atrophy Diseases 0.000 claims 1
- 208000002691 Choroiditis Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010059239 Leukaemic retinopathy Diseases 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 206010025415 Macular oedema Diseases 0.000 claims 1
- 208000003926 Myelitis Diseases 0.000 claims 1
- 206010029113 Neovascularisation Diseases 0.000 claims 1
- 208000003435 Optic Neuritis Diseases 0.000 claims 1
- 201000010183 Papilledema Diseases 0.000 claims 1
- 206010033708 Papillitis Diseases 0.000 claims 1
- 208000003971 Posterior uveitis Diseases 0.000 claims 1
- 201000007527 Retinal artery occlusion Diseases 0.000 claims 1
- 206010038848 Retinal detachment Diseases 0.000 claims 1
- 206010038910 Retinitis Diseases 0.000 claims 1
- 206010038926 Retinopathy hypertensive Diseases 0.000 claims 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 1
- 206010064930 age-related macular degeneration Diseases 0.000 claims 1
- 208000007502 anemia Diseases 0.000 claims 1
- 206010003074 arachnoiditis Diseases 0.000 claims 1
- 206010063452 arteriosclerotic retinopathy Diseases 0.000 claims 1
- 230000037444 atrophy Effects 0.000 claims 1
- 230000003915 cell function Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000006196 drop Substances 0.000 claims 1
- 239000003889 eye drop Substances 0.000 claims 1
- 229940012356 eye drops Drugs 0.000 claims 1
- 230000004438 eyesight Effects 0.000 claims 1
- 201000001948 hypertensive retinopathy Diseases 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 208000002780 macular degeneration Diseases 0.000 claims 1
- 201000010230 macular retinal edema Diseases 0.000 claims 1
- 208000012286 optic choroid disease Diseases 0.000 claims 1
- 210000001328 optic nerve Anatomy 0.000 claims 1
- 201000002166 optic papillitis Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000004264 retinal detachment Effects 0.000 claims 1
- 208000004644 retinal vein occlusion Diseases 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000004382 visual function Effects 0.000 claims 1
Images
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32333810P | 2010-04-12 | 2010-04-12 | |
| US32334210P | 2010-04-12 | 2010-04-12 | |
| US61/323,342 | 2010-04-12 | ||
| US61/323,338 | 2010-04-12 | ||
| US32681110P | 2010-04-22 | 2010-04-22 | |
| US61/326,811 | 2010-04-22 | ||
| US36294510P | 2010-07-09 | 2010-07-09 | |
| US61/362,945 | 2010-07-09 | ||
| US40823710P | 2010-10-29 | 2010-10-29 | |
| US61/408,237 | 2010-10-29 | ||
| PCT/JP2011/059479 WO2011129461A1 (en) | 2010-04-12 | 2011-04-12 | Method and ophthalmic composition for treating retinal disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015194346A Division JP2016026182A (ja) | 2010-04-12 | 2015-09-30 | 網膜疾患を処置するための方法および眼科用組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013528563A JP2013528563A (ja) | 2013-07-11 |
| JP2013528563A5 true JP2013528563A5 (cg-RX-API-DMAC7.html) | 2014-05-29 |
| JP5878128B2 JP5878128B2 (ja) | 2016-03-08 |
Family
ID=44798822
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012544363A Active JP5878128B2 (ja) | 2010-04-12 | 2011-04-12 | 網膜疾患を処置するための方法および眼科用組成物 |
| JP2012547193A Expired - Fee Related JP5686819B2 (ja) | 2010-04-12 | 2011-04-12 | 黄斑浮腫を処置するための医薬組成物 |
| JP2015194346A Pending JP2016026182A (ja) | 2010-04-12 | 2015-09-30 | 網膜疾患を処置するための方法および眼科用組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012547193A Expired - Fee Related JP5686819B2 (ja) | 2010-04-12 | 2011-04-12 | 黄斑浮腫を処置するための医薬組成物 |
| JP2015194346A Pending JP2016026182A (ja) | 2010-04-12 | 2015-09-30 | 網膜疾患を処置するための方法および眼科用組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20110275715A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2558103A4 (cg-RX-API-DMAC7.html) |
| JP (3) | JP5878128B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20130050939A (cg-RX-API-DMAC7.html) |
| CN (2) | CN102946883A (cg-RX-API-DMAC7.html) |
| AR (1) | AR080888A1 (cg-RX-API-DMAC7.html) |
| CA (2) | CA2795720A1 (cg-RX-API-DMAC7.html) |
| TW (2) | TW201204366A (cg-RX-API-DMAC7.html) |
| WO (2) | WO2011129461A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112012012767A2 (pt) * | 2009-11-27 | 2016-09-06 | R Tech Ueno Ltd | método para avaliar um agente que é útil para o tratamento de olho seco e/ou lesão corneana e conjutiva e uma composição farmacêutica obtida pelo método |
| EP2696876A4 (en) * | 2011-04-12 | 2014-09-03 | R Tech Ueno Ltd | AQUEOUS OPHTHALMIC COMPOSITION |
| CA2865132A1 (en) * | 2012-02-22 | 2013-08-29 | Trustees Of Tufts College | Compositions and methods for ocular delivery of a therapeutic agent |
| CA3034547C (en) * | 2016-08-24 | 2021-04-13 | National Institute Of Biological Sciences, Beijing | Entacapone-related compounds to treat macular degeneration |
| JP2022521851A (ja) * | 2019-04-03 | 2022-04-12 | レジェンクスバイオ インコーポレーテッド | 眼の病態に対する遺伝子療法 |
| IL292350A (en) | 2019-10-30 | 2022-06-01 | Perfuse Therapeutics Inc | Treatment of ocular diseases using endothelin receptor antagonists |
| IL294873A (en) | 2020-02-06 | 2022-09-01 | Perfuse Therapeutics Inc | Preparations for the treatment of eye diseases |
| EP4329753A4 (en) | 2021-04-30 | 2025-02-26 | Perfuse Therapeutics, Inc. | PHARMACEUTICAL COMPOSITIONS AND INTRAVITREAL DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF EYE DISEASES |
| AU2022306289A1 (en) | 2021-07-09 | 2024-01-18 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| WO2023043816A1 (en) | 2021-09-17 | 2023-03-23 | Aligos Therapeutics, Inc. | Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1251862B1 (en) * | 2000-01-18 | 2008-10-01 | Merck & Co., Inc. | Ophthalmic compositions for treating ocular hypertension |
| PE20020146A1 (es) * | 2000-07-13 | 2002-03-31 | Upjohn Co | Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2) |
| WO2003020283A2 (en) * | 2001-08-29 | 2003-03-13 | Novartis Ag | Method for treating diabetic retinopathy |
| KR20120005052A (ko) * | 2003-08-21 | 2012-01-13 | 수캄포 아게 | 안과용 조성물 |
| US20050119262A1 (en) * | 2003-08-21 | 2005-06-02 | Pharmacia Corporation | Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent |
| WO2006082588A2 (en) * | 2005-02-07 | 2006-08-10 | Pharmalight Inc. | Method and device for ophthalmic administration of active pharmaceutical ingredients |
| US20100087540A1 (en) * | 2008-10-07 | 2010-04-08 | R-Tech Ueno, Ltd. | Pharmaceutical composition |
-
2011
- 2011-04-12 EP EP11768976.0A patent/EP2558103A4/en not_active Withdrawn
- 2011-04-12 US US13/084,927 patent/US20110275715A1/en not_active Abandoned
- 2011-04-12 KR KR1020127029449A patent/KR20130050939A/ko not_active Withdrawn
- 2011-04-12 WO PCT/JP2011/059479 patent/WO2011129461A1/en not_active Ceased
- 2011-04-12 JP JP2012544363A patent/JP5878128B2/ja active Active
- 2011-04-12 TW TW100112738A patent/TW201204366A/zh unknown
- 2011-04-12 US US13/084,982 patent/US20110275711A1/en not_active Abandoned
- 2011-04-12 CN CN2011800290140A patent/CN102946883A/zh active Pending
- 2011-04-12 CN CN201180028968XA patent/CN102933217A/zh active Pending
- 2011-04-12 CA CA2795720A patent/CA2795720A1/en not_active Abandoned
- 2011-04-12 CA CA2795723A patent/CA2795723A1/en not_active Abandoned
- 2011-04-12 WO PCT/JP2011/059474 patent/WO2011129457A1/en not_active Ceased
- 2011-04-12 JP JP2012547193A patent/JP5686819B2/ja not_active Expired - Fee Related
- 2011-04-12 AR ARP110101238A patent/AR080888A1/es unknown
- 2011-04-12 KR KR1020127029562A patent/KR20130099812A/ko not_active Withdrawn
- 2011-04-12 TW TW100112624A patent/TW201141486A/zh unknown
- 2011-04-12 EP EP11768978.6A patent/EP2558104A4/en not_active Withdrawn
-
2015
- 2015-09-30 JP JP2015194346A patent/JP2016026182A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013528563A5 (cg-RX-API-DMAC7.html) | ||
| Mayama | Calcium channels and their blockers in intraocular pressure and glaucoma | |
| EP4360709A3 (en) | Use of a vegf antagonist to treat angiogenic eye disorders | |
| JP2010285434A5 (cg-RX-API-DMAC7.html) | ||
| JP2008538215A5 (cg-RX-API-DMAC7.html) | ||
| PH12013500577B1 (en) | Compositions and methods for treating ocular edema, neovascularization and related diseases | |
| RU2015117536A (ru) | Vegf-нейтрализирующие пролекарства для лечения офтальмологических заболеваний | |
| JP2015526467A5 (cg-RX-API-DMAC7.html) | ||
| WO2015135306A1 (zh) | 青蒿素及其衍生物在制备防治眼科血管性疾病药物中的应用及药物组合物 | |
| MX2019008963A (es) | Composicion para la prevencion o el tratamiento de deterioros visuales que comprenden acido ursodesoxicolico. | |
| RU2012134639A (ru) | Фармацевтический препарат для предупреждения и лечения нарушений, сопровождающихся глазным ангиогенезом и/или повышенной проницаемостью сосудов глаза | |
| Xin et al. | Ophthalmic drops with nanoparticles derived from a natural product for treating age-related macular degeneration | |
| WO2008020032A8 (en) | Use of 2,5-dihydroxybenzene derivatives for the treatment of ocular diseases | |
| FI2765988T3 (fi) | Silmäkoostumus, joka sisältää bromfenaakkia, jolla on parannettu biologinen hyötyosuus | |
| WO2008152507A3 (en) | Compositions and methods for treating ophthalmic disorders | |
| NZ594728A (en) | Use of deferiprone for treatment and prevention of iron-related eye disorders | |
| HRP20192256T1 (hr) | Uporaba kabergolina u liječenju očnih bolesti uzrokovanih povišenim čimbenikom vaskularnog endotelnog rasta | |
| Day et al. | Timolol 0.5%/dorzolamide 2% fixed combination vs timolol maleate 0.5% and unoprostone 0.15% given twice daily to patients with primary open-angle glaucoma or ocular hypertension | |
| JP7461667B2 (ja) | ナノ低分子ペプチドｆｈ及びその眼底血管疾患の治療用薬物又は予防用薬物の調製への使用 | |
| Querques et al. | Intravitreal pegaptanib sodium for Irvine-Gass syndrome | |
| JP2014521648A5 (cg-RX-API-DMAC7.html) | ||
| JP2015027980A5 (cg-RX-API-DMAC7.html) | ||
| Mautino et al. | Case studies on adverse effects of drugs used in ocular treatment | |
| HK1189820A (en) | Use of a vegf antagonist to treat angiogenic eye disorders | |
| Novytskvy et al. | EFFICACY OF TRABECULAR ABLATION THROUGH THE ANTERIOR CHAMBER ANGLE IN OPEN-ANGLE GLAUCOMA |